sestamibi

(redirected from Cardiolite)
Also found in: Medical.

ses·ta·mi·bi

 (sĕs′tə-mē′bē)
n.
An injectable drug containing an isotope of the radioactive element technetium, used in nuclear medicine imaging primarily to visualize the heart muscle, parathyroid glands, and breast tissue.

[sesta-, perhaps alteration (influenced by Latin sex, six) of hexakis-, prefix indicating six in chemical names (from the six ligands bound to its central technetium ion ) + m(ethoxy)i(so)b(utyl)i(sonitrile).]
References in periodicals archive ?
The influence of generator eluate on the radiochemical purity of [sup.99][Tc.sup.m]-sestamibi prepared using fractionated Cardiolite kits.
In February 2012, Lantheus entered into a manufacturing and supply agreement with JHS for DEFINITY, as well as the manufacture and supply of Cardiolite and Neurolite, which are also manufactured by Ben Venue.
The patient received a Cardiolite (technetium Tc99m sestamibi) exam that was negative for ischemia, but showed an area of increased activity in the left breast.
During that time, I talked my way into three stress tests, more than a dozen different blood work-ups; a Cardiolite scan in which they injected a radioactive isotope into my blood stream and then did a magnetic imaging of my heart and arteries; and finally, the Cadillac of cardiac diagnostic tests--an angiogram.
A cardiolite stress test and an abnormal electrocardiogram suggested that an area of the patient's heart was not getting enough blood.
Title: Cardiolite Predict It, or Image It Campaign Agency: The Hal Lewis Group, Inc.
Among her successes: a bladder cancer detection product for Matritech, a hip replacement compound for Zimmer and a Bristol-Myers Squibb medical imaging product called Cardiolite, which has generated more than $20 million in royalties for joint sponsors MIT and Harvard.
The study was supported, in part, by Fujisawa, which markets a formulation of adenosine (Adenoscan), and by Bristol-Myers Squibb, which markets technetium Tc99m sestamibi (Cardiolite).
The study was supported, in part, by Fujisawa, which markets a formulation of adenosine (Adeno-scan), and by Bristol-Myers Squibb, which markets technetium Tc99m sestamibi (Cardiolite).
With this acquisition, Bristol-Myers Squibb gains several important in-line products, including Sustiva [TM] (efavirenz), the leading non-nucleoside reverse transcriptase inhibitor for the treatment of HIV/AIDS; Coumadin [R] (warfarin sodium tablets, USP), a widely used oral blood anticoagulant; and Cardiolite [R], a leading cardiovascular medical imaging agent.
Tc 99m sestamibi, marketed under the name Cardiolite (DuPont Pharmaceuticals, Wilmington, Del), readily collects in viable myocardial cells.